Utilization of the multiple sclerosis functional composite as an outcome measure in the phase 3 trial of interferon beta-1a (Avonex®) in secondary progressive multiple sclerosis (IMPACT)

被引：0
|
作者：
Cohen, JA
Cutter, GC
Simonian, NA
Goodman, AD
Heidenreich, FR
Simon, JH
Whitaker, JN
机构：
来源：
NEUROLOGY | 1999年 / 52卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A548 / A549
页数：2
相关论文
共 50 条
  • [21] Appropriate use of interferon beta-1a in multiple sclerosis
    Jacobs, L
    Brownscheidle, CM
    BIODRUGS, 1999, 11 (03) : 155 - 163
  • [22] Interferon beta-1a overdose in a multiple sclerosis patient
    Falcone, NP
    Nappo, A
    Neuteboom, B
    ANNALS OF PHARMACOTHERAPY, 2005, 39 (11) : 1950 - 1952
  • [23] Appropriate Use of Interferon Beta-1a in Multiple Sclerosis
    Lawrence Jacobs
    Carol M. Brownscheidle
    BioDrugs, 1999, 11 : 155 - 163
  • [24] Autoimmune hepatitis and interferon beta-1a for multiple sclerosis
    Duchini, A
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (03): : 767 - 768
  • [25] QUALITY OF LIFE IN RELAPSING REMMITING MULTIPLE SCLEROSIS: INFLUENCE OF INTERFERON BETA-1A (AVONEX AND CINNOVEX) TREATMENT
    Shahtaheri, R. S.
    Hatam, N.
    VALUE IN HEALTH, 2016, 19 (07) : A436 - A436
  • [26] Immunomodulatory effects of interferon beta-1a in multiple sclerosis
    Liu, ZG
    Pelfrey, CM
    Cotleur, A
    Lee, JC
    Rudick, RA
    JOURNAL OF NEUROIMMUNOLOGY, 2001, 112 (1-2) : 153 - 162
  • [27] A study of the effect of gender on interferon beta-1a (Avonex® 30 mcg) treatment in patients with multiple sclerosis
    Munschauer, FE
    Herndon, R
    Sandrock, AW
    Tsao, E
    Berkhoff, JE
    Stubbendick, A
    MULTIPLE SCLEROSIS, 2005, 11 : S78 - S78
  • [28] Mixed Panniculitis Secondary to Interferon beta-1a Therapy in a Woman With Multiple Sclerosis
    Cuesta, L.
    Moragon, M.
    Perez-Crespo, M.
    Onrubia, J.
    Garcia, M.
    ACTAS DERMO-SIFILIOGRAFICAS, 2013, 104 (03): : 257 - 259
  • [29] Development of a multiple sclerosis functional composite as a clinical trial outcome measure
    Cutter, GR
    Baier, ML
    Rudick, RA
    Cookfair, DL
    Fischer, JS
    Petkau, J
    Syndulko, K
    Weinshenker, BG
    Antel, JP
    Confavreux, C
    Ellison, GW
    Lublin, F
    Miller, AE
    Rao, SM
    Reingold, S
    Thompson, A
    Willoughby, E
    BRAIN, 1999, 122 : 871 - 882
  • [30] Significance of serum neutralising antibodies to Avonex' (IFN beta-1a) in multiple sclerosis
    Rudick, RA
    Jones, W
    Alam, J
    Simonian, N
    Campion, M
    Jacobs, L
    Herndon, R
    Richert, J
    Salazar, A
    Cookfair, D
    Simon, J
    Coats, M
    Goodkin, D
    Mass, M
    NEUROLOGY, 1997, 48 (03) : 5003 - 5003
12345